Wall Street Zen downgrades ACADIA Pharmaceuticals while upgrading Acadia Realty Trust

Wall Street Zen moved ADARx Pharmaceuticals to Hold, downgraded ACADIA Pharmaceuticals from Buy to Hold, and raised Acadia Realty Trust from Sell to Hold. ACADIA’s rating change contrasts with a broader analyst consensus of Moderate Buy, while Acadia Realty also retains a Moderate Buy consensus despite the upgrade. Separately, HC Wainwright reaffirmed Buy ratings on Celldex Therapeutics and Connect Biopharma; other analysts remain broadly positive on both companies, though Connect Biopharma has also received a Sell rating. The reports reflect mixed, company-specific analyst views rather than a single directional shift across the stocks.